Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 1, 2006

Sapient Discovery Provides Insight on Lpath’s Cancer Drug Candidate

  • Sapient Discovery and Lpath reported the successful completion of a study to assess Lpath’s agent to treat cancer and various ocular diseases. The collaboration used Sapient Discovery's computational platform to understand the binding properties of Lpath's humanized sphingomab antibody to its target, sphingosine-1-phosphate (S1P).

    "Sapient Discovery's proprietary Genes-to-Leads technology created dynamic 3-D structural models of the binding of Sphingomab to S1P," explains Kal Ramnarayan Ph.D., president and CSO of Sapient Discovery, "This has provided valuable insights for the Lpath research team with significant efficiency and cost savings to Lpath."

    Lpath says it is the first to generate therapeutic Mabs against S1P, a bioactive lipid involved in angiogenesis and the progression of cancer.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »